Skip to main content
Premium Trial:

Request an Annual Quote

Pew Charitable Trusts Names 22 Early-Career Researchers Scholars in the Biomedical Sciences


The Pew Charitable Trusts named 22 early-career researchers in the US as its Pew Scholars in the Biomedical Sciences today. Each will receive $240,000 over four years to pursue the research of their choice without restriction.

According to the charitable organization, the recipients' research foci explore a range of human health issues "from antibiotic-resistant infections to liver disease and cancer."

Among the 22 newly named scholars are the University of Utah's Nels Elde, whose research focuses on evolutionary genetics and cell biology, Duke University Medical Center's Donald Fox, who studies tissue repair and genome stability, Salil Lachke at the University of Delaware, who works on developmental genetics, Brown University's Sohini Ramachandran, whose research focuses on human genomics and evolution, University of Pennsylvania's Kathryn Wellen, who investigates cancer metabolism and epigenetics, Saint Louis University's Mee-Ngan Yap, who works on molecular microbiology, and Wenjun Zhang at the University of California, Berkeley, who is researching chemical and synthetic biology.

"During these challenging budgetary times when traditional sources of funding are becoming even harder for scientists to obtain, we are proud to back our country's most promising scientists," Pew Charitable Trusts President and CEO Rebecca Rimel says in a statement. "This funding comes at points in the scholars' professional lives when they often are the most innovative. While this program is a bold investment for us, it has paid incalculable dividends due to our scholars' record of producing groundbreaking research."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more